Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided prophylaxis dosing in hemophilia A and B
2018-003869-33Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Factor VIII and coagulation factor IX in hemophilia A and hemophilia B (HB), sponsored by Erasmus MC. Primary endpoint: Predictive performance of population PK modeling. Started Dec 2018; status: active.
02
Drugs
Factor VIIIcoagulation factor IX
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2018-003869-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003869-33.